What are the strengths and weaknesses of conventional measures of RA disease activity (i.e., ACR scores) as compared to the increasingly important patient-reported outcomes (PROS)?

What are the strengths and weaknesses of conventional measures of RA disease activity (i.e., ACR scores) as compared to the increasingly important patient-reported outcomes (PROS)?

What are the strengths and weaknesses of conventional measures of RA disease activity (i.e., ACR scores) as compared to the increasingly important patient-reported outcomes (PROS) that are being used in clinical trials?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Yvonne Sherrer, MD

Yvonne Sherrer, MD

Medical Director/Director of Clinical Research
Centre for Rheumatology, Immunology and Arthritis
Fort Lauderdale, FL